Abstract
Methods: The objectives of this trial are to evaluate the safety and pharmacokinetic (PK) behavior of CF102 in HCC patients. Utilizing a “3+3” design, successive cohorts of patients with advanced HCC were enrolled at CF 102 doses of 1, 5, or 25 mg twice daily, given orally in continuous cycles of 28 days each. Progression to a higher-dose cohort was based on first cycle toxicity. Standard safety and PK assessments were performed; αfetoprotein (AFP) levels were obtained each cycle, and tumor imaging was obtained every other cycle.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
